Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis

Figures & data

Table 1 The General Clinical Data of Elderly Patients with ES-SCLC Before and After PSM

Characteristics	Before PSM			After PSM
	TRT	noTRT	P value	TRT	noTRT	P value
(n=44)	(n=49)	(n=40)	(n=40)
Age:			0.388			0.556
<75	10	39		34	32
≥75	6	38		6	8
Sex: male	37	36	0.213	33	34	0.762
Smoking index:  ≥400	36	37	0.391	32	32	0.800
Weight loss	10	7	0.293	6	7	0.762
KPS score: ≥80	39	45	0.602	36	36	1.000
Metastatic sites:			0.140			0.329
Brain	16	11		14	10
Others	28	38		26	30
Numbers of metastases:			0.017			0.143
0–1	18	9		15	9
≥2	26	40		25	31
Numbers of chemotherapy cycles:			0.491			1.000
1–3	9	13		9	9
≥4	35	36		31	31
Chemotherapy efficacy:			0.056			0.112
Effective	23	16		20	13
Ineffective	21	33		20	27

Abbreviations: ES-SCLC, extensive-stage small cell lung cancer; PSM, propensity score matching; TRT, thoracic radiotherapy; noTRT, no thoracic radiotherapy; KPS, Karnofsky performance status.

Table 2 The Prescription Dose of Each Elderly ES-SCLC Patients in TRT Group After PSM

Number of Patients	Prescription Dose (Gy)	Times
12	60	30
1	56	28
1	50.4	28
3	54	27
1	52.5	25
8	50	25
5	45	15
1	37.5	15
2	36	12
6	30	10

Table 3 Survival Comparison of Elderly ES-SCLC Patients with TRT or noTRT After PSM

Characteristics	TRT (n = 40)	noTRT (n = 40)	P value
Overall survival:			0.000
Median(months)	13.2	7.5
1-year(%)	55%	25%
2-year(%)	11.4%	0%
Progression-free survival:			0.000
Median(months)	8.9	5.0
1-year(%)	32.1%	0%
2-year(%)	8%	0%
Local recurrence-free survival:			0.000
Median(months)	10.3	5.1
1-year(%)	31%	2.6%
2-year(%)	5.6%	0%

Abbreviations: ES-SCLC, Extensive-stage small cell lung cancer; PSM, propensity score matching; TRT, thoracic radiotherapy; noTRT, no thoracic radiotherapy.

Figure 1 Overall survival comparison of elderly ES-SCLC patients with TRT or noTRT after PSM.

Figure 2 Progression-free survival comparison of elderly ES-SCLC patients with TRT or noTRT after PSM.

Figure 3 Local recurrence-free survival comparison of elderly ES-SCLC patients with TRT or noTRT after PSM.

Table 4 Univariate and Multivariate Prognostic Analysis of Elderly ES-SCLC Patients After PSM

Characteristics	Univariate Analysis (OS)			Multivariate Analysis (OS)
	Median	2-Year	P value	RR value	95% CI	P value
(Months)	(%)
Age:			0.945
<75	10.4	5.3
≥75	7.9	7.1
Sex:			0.520
Male	10.4	8.4
Female	10.2	0
KPS score:			0.142
<80	5.8	0
≥80	10.4	7.8
Weight loss:			0.128
Yes	8.4	0
No	10.4	8.4
Smoking index:			0.898
<400	10.2	7.7
≥400	10.3	7.3
Metastatic sites:			0.297
Brain	12.3	5.6
Others	10.2	7.1
Numbers of metastases:			0.000	6.026	2.877–12.622	0.000
0–1	14.7	23.8
≥2	7.9	0
Chemotherapy regimens			0.502
EP	9.0	5.0
EC	10.7	9.0
Numbers of chemotherapy cycles:			0.014	0.226	0.115–0.446	0.000
1–3	4.4	0
≥4	11.0	9.4
Chemotherapy efficacy:			0.000	0.431	0.256–0.767	0.002
Effective	14.0	15.2
Ineffective	7.9	2.1
Receipt of TRT			0.000	0.483	0.297–0.783	0.003
Yes	13.2	11.4
No	7.5	0
Time between chemotherapy start and TRT end			0.050	1.007	0.948–1.069	0.824
<4.7 months	14.3	0
≥4.7 months	13.6	27.2

Abbreviations: ES-SCLC, extensive-stage small cell lung cancer; PSM, propensity score matching; OS, overall survival; KPS, Karnofsky Performance Status; TRT, thoracic radiotherapy.

Table 5 The Comparison of Survival in Different Induction Chemotherapy Efficacy Groups of Elderly ES-SCLC Patients After PSM

Characteristics	Ineffective Group (n=47)			Effective Group (n=33)
	TRT	noTRT	P value	TRT	noTRT	P value
(n=20)	(n=27)	(n=20)	(n=13)
Overall survival:
Median(months)	10.3	7.3	0.068	16.2	8.4	0.003
1-year (%)	0	0		75	30.8
2-year (%)	0	0		20	0
Progression-free survival:
Median(months)	8.1	3.6	0.001	10.5	6.3	0.001
1-year (%)	0	0		45	0
2-year (%)	0	0		15	0
Local recurrence-free survival:
Median(months)	8.5	4.8	0.003	12.2	6.3	0.000
1-year (%)	0	0		50.3	0
2-year (%)	0	0		11.2	0

Abbreviations: ES-SCLC, extensive-stage small cell lung cancer; PSM, propensity score matching; TRT, thoracic radiotherapy; noTRT, no thoracic radiotherapy.